Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Compare
Compare
Traded in other countries / regions
ATAI.USA9VC.GermanyATAI.Mexico IPO Date
2021-07-14Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.5 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.88 | |||||
| Beneish M-Score | 1.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | 14.9 | |||||
| 3-Year FCF Growth Rate | -57.7 | |||||
| 3-Year Book Growth Rate | 34.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 302.13 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.9 | |||||
| 9-Day RSI | 56.84 | |||||
| 14-Day RSI | 53.91 | |||||
| 6-1 Month Momentum % | -49.74 | |||||
| 12-1 Month Momentum % | -17.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.68 | |||||
| Quick Ratio | 6.68 | |||||
| Cash Ratio | 5.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 | |||||
| Shareholder Yield % | -1.58 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -28353.97 | |||||
| Net Margin % | -15363.23 | |||||
| FCF Margin % | -20757.79 | |||||
| ROE % | -26.11 | |||||
| ROA % | -21.67 | |||||
| ROIC % | -112.8 | |||||
| 3-Year ROIIC % | -34.78 | |||||
| ROC (Joel Greenblatt) % | -2499.31 | |||||
| ROCE % | -21.79 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 590 | |||||
| PB Ratio | 1.18 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | -2.37 | |||||
| EV-to-Forward-EBIT | -0.86 | |||||
| EV-to-EBITDA | -2.39 | |||||
| EV-to-Forward-EBITDA | -0.99 | |||||
| EV-to-Revenue | 342.03 | |||||
| EV-to-Forward-Revenue | 167.91 | |||||
| EV-to-FCF | -1.63 | |||||
| Price-to-Net-Current-Asset-Value | 2.8 | |||||
| Price-to-Net-Cash | 4.96 | |||||
| Earnings Yield (Greenblatt) % | -42.19 | |||||
| FCF Yield % | -40.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.353 | ||
| EPS (TTM) (€) | -0.357 | ||
| Beta | 0.86 | ||
| Volatility % | 61.9 | ||
| 14-Day RSI | 53.91 | ||
| 14-Day ATR (€) | 0.052058 | ||
| 20-Day SMA (€) | 1.047465 | ||
| 12-1 Month Momentum % | -17.49 | ||
| 52-Week Range (€) | 0.9502 - 2.369 | ||
| Shares Outstanding (Mil) | 167.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ATAI Life Sciences NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(STU:9VC)'s stock price today?
The current price of STU:9VC is €1.09. The 52 week high of STU:9VC is €2.37 and 52 week low is €0.95.
When is next earnings date of ATAI Life Sciences NV(STU:9VC)?
The next earnings date of ATAI Life Sciences NV(STU:9VC) is 2024-11-14 Est..
Does ATAI Life Sciences NV(STU:9VC) pay dividends? If so, how much?
ATAI Life Sciences NV(STU:9VC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers